AVE 20.0% 0.2¢ avecho biotechnology limited

ena feeds 9 months on, page-73

  1. 30 Posts.
    Tangentland,

    Yes, probably the best move for early revenue this company has made was the equine deal. (R & D does not generate revenue immediately.) To have legs a product needs distribution which it brought with the JV, and then performance which will show through the sales.
    As this company already had clients it makes it easy to talk trainers/studs into giving these new products a try. Its an industry of individuals driven by performance. SOME WILL SEE AN IMPROVEMENT WHEN THEN IS NONE. Others will be advised by their vets, which is the rule with overseas clients and bigger operations in australia.
    It all comes back to repeat sales. Generally a small percentage of a stable will try a new product.usually the ones that need improvement the most. If a product works it actually helps these the most witch then helps get the stable on side. Do you know if the equine company has increased its sales team?
    When did sales actually start?
 
watchlist Created with Sketch. Add AVE (ASX) to my watchlist
(20min delay)
Last
0.2¢
Change
-0.001(20.0%)
Mkt cap ! $6.338M
Open High Low Value Volume
0.2¢ 0.2¢ 0.2¢ $29.34K 14.67M

Buyers (Bids)

No. Vol. Price($)
29 33474953 0.2¢
 

Sellers (Offers)

Price($) Vol. No.
0.3¢ 44170247 21
View Market Depth
Last trade - 11.59am 07/10/2024 (20 minute delay) ?
AVE (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.